Although juvenile-onset recurrent respiratory papillomatosis (JoRRP) generally involves a benign tumor on the larynx and other respiratory tract areas, almost all patients with this disease require repeated surgical intervention (to prevent airway obstruction during the course of illness) and various adjuvant therapies such as interferon, cidofovir, acyclovir, ribavirin, indole-3-carbinol, HspE7, mumps vaccine, photodynamic therapy, propranolol, cimetidine, and bevacizumab. Some case reports recently described the effectiveness of the quadrivalent human papillomavirus vaccine (HPV4) as an adjuvant therapy. On the basis of these reports, we administered HPV4 to a 2-year-old boy with JoRRP. However, no therapeutic effect was found. A review of the available literature revealed that current evidence for the effectiveness of therapeutic HPV4 and other adjuvant therapies for JoRRP is inconsistent. Therefore, the prophylactic use of currently available HPV vaccine for adolescents is the most effective strategy for preventing not only anogenital cancers but also genital warts, which might be a risk factor for JoRRP among their children in the future.
Juvenile-onset recurrent respiratory papillomatosis (JoRRP) is characterized by the growth of a benign tumor on the larynx and other areas of the respiratory tract. Although JoRRP is a relatively rare disease, once it develops, almost all patients with the disease require repeated surgical intervention (to prevent airway obstruction during the course of illness) and various adjuvant therapies such as interferon (IFN), cidofovir, acyclovir, ribavirin, indole-3-carbinol (I3C), HspE7, mumps vaccine, photodynamic therapy (PDT), propranolol, cimetidine, and bevacizumab. The quadrivalent human papillomavirus vaccine (HPV4), which protects against human papillomavirus (HPV) types 6, 11, 16, and 18, was administered recently to some patients as an adjuvant therapy [1] [2] [3] [4] [5] [6] [7] [8] .
Here, we report the case of a 2-year-old boy with JoRRP who was given HPV4 as adjuvant therapy. This study was approved by the institutional review board of St Marianna University School of Medicine.
CASE REPORT: HISTORY AND CLINICAL EXAMINATION
The index case-patient is a 2-year-old boy who was born at term via normal vaginal delivery. He was previously healthy with no respiratory tract abnormality or known immunodeficiency. His mother had condyloma acuminatum at the time of his birth. Beginning 1 month before referral to our hospital, the patient gradually developed hoarseness of voice and a barking cough. His respiratory condition gradually worsened, and he was transferred to our hospital by ambulance because of severe inspiratory stridor. Direct laryngoscopy was performed by an otolaryngologist, and laryngeal papillomatosis was revealed ( Figure 1A ). The patient was intubated immediately. On day 2 of admission, surgical debridement using a microdebrider was performed, and all visible papilloma tissue was removed carefully. Tissue samples were sent for an HPV polymerase chain reaction assay, and HPV type 11 was identified. The patient then required repeat surgical debridement every 3 to 5 weeks to prevent obstruction by the recurrence of papillomatosis on his larynx. After the fourth surgery, because of his frequent recurrences, we decided to introduce HPV4 as adjuvant therapy for his JoRRP. The vaccine was administered at 0, 2, and 6 months (0.5 mL intramuscularly), consistent with the administration schedule recommended at that time. When the patient received the second dose, we examined his larynx by direct laryngoscopy and confirmed the recurrence of papillomatosis around his vocal cords ( Figure 1B) . One month after his second dose, he required emergency tracheotomy as a result of severe laryngeal obstruction. He then received his third inoculation as scheduled. Three years after completing the 3-dose HPV4 series, he continued to require microlaryngoscopic surgery every 1 to 2 months.
DISCUSSION
In this case study, we administered HPV4 as an adjuvant therapy to a 2-year-old boy who required repeated surgical intervention for JoRRP caused by HPV type 11. Although he received all 3 HPV4 doses at the appropriate intervals, no therapeutic effect was seen.
JoRRP is characterized by benign tumors of the larynx and other areas of the respiratory tract. Most cases of JoRRP result from HPV type 6 or 11 [9] , and children who were born to mothers with condylomas during pregnancy are known to have a 200-fold risk of acquiring JoRRP [10] . The mean age at which JoRRP is diagnosed is approximately 4 years, and the most common presenting symptom is hoarseness [9] . The reported prevalences of JoRRP vary widely across different countries and studies. The overall incidence rates reported from Norway [11] and the United States [12] are 0.17 and 4.3 per 100 000, respectively. Although some patients recover spontaneously, most children with JoRRP require repeated surgical intervention during the course of their illness to prevent airway obstruction. Most patients with JoRRP experience less need for debulking surgeries over time [9] , but sometimes the disease causes sudden death as a result of asphyxia.
To reduce the burden of repeated surgical intervention, numerous adjuvant therapies have been used for patients with JoRRP. These therapies include IFN, cidofovir, acyclovir, ribavirin, I3C, HspE7, mumps vaccine, PDT, propranolol, cimetidine, and bevacizumab [13, 14] . Indeed, among 150 (21%) of the 700 cases of JoRRP in the United States, a least 1 adjuvant therapy was used along with repeated basic surgery [15] . However, little evidence exists to demonstrate definitive efficacy for any of these adjuvant approaches.
Quadrivalent Human Papillomavirus Vaccine
Some case reports recently described partial or complete remission of disease among patients with JoRRP when HPV4 was used as an adjuvant therapy [1] [2] [3] [4] [5] [6] 8] . HPV4 is currently licensed in the United States for use in adolescents and young adults aged 9 to 26 years for the prevention of genital warts, cervical cancer, and other HPV-associated precancerous lesions and malignancies, and it has been added to universal vaccination programs in many countries, including Japan. The primary purpose of HPV4 vaccination is to prevent HPV-related disease in adolescents and adults before exposure to the HPV types included in the vaccine.
In 2008, Förster et al [1] reported the case of a 2-year-old boy with JoRRP attributable to HPV types 6 and 11. HPV4 was administered as adjuvant therapy, and he achieved remission over a 10-month period after 3 doses of the vaccine. Mudry et al [2] also reported the effectiveness of HPV4 in a 5-year-old girl with JoRRP attributable to HPV type 11. Although other case reports [3] [4] [5] [6] 8] that describe the effectiveness of HPV4 for JoRRP have been published, each of them includes only a small number of cases (Table 1) . Chirilă et al [16] reported the administration of HPV4 to 13 patients with RRP whose former adjuvant therapy (cidofovir) was ineffective, and clinical response was observed in 11 (85%) of them. However, some of their case-patients had adult-onset recurrent respiratory papillomatosis (AoRRP).
The mechanism that underlies the vaccine's potential therapeutic efficacy against JoRRP is unknown. In general, HPV4 is composed of virus-like particles formed by L1 capsid proteins of HPV types 6, 11, 16, and 18. L1 is the major capsid protein of the papillomavirus, and it releases the viral DNA into the newly infected host cell. Although HPV4 induces a specific antibody response in patients with JoRRP [17] , the primary purpose of vaccination is to prevent future HPV infection rather than provide treatment for existing infection. However, Young et al [6] hypothesized that vaccination can lead to remission in patients with JoRRP because of the combination of sufficiently high antibody titers to prevent disease recurrence and complete surgical or chemical removal of existing lesions. In contrast, Hermann et al [7] reported the cases of 9 patients with JoRRP aged 9 to 17 years with HPV type 6 or 11 who were treated with surgical therapy and HPV4, and no therapeutic effect was found. All 9 patients in the case series had a relapse after vaccination (Table 1) . Likewise, our patient experienced a similar outcome, which suggests that HPV4 might not be an effective adjuvant therapy for all patients with JoRRP.
The inconsistent findings from published reports highlight the challenge in rigorously evaluating the therapeutic efficacy of currently available HPV vaccines for the management of JoRRP. JoRRP is a relatively rare disease, which makes it difficult to conduct large randomized controlled trials or perform a prospective observational study. In addition, the clinical course of patients with JoRRP intrinsically is variable because of a range of individual factors. Last, in published studies, many patients also received other adjuvant therapies, which makes it difficult to determine the independent effect of HPV4. Therefore, the therapeutic role of HPV4 for JoRRP is limited. Available evidence also indicates limited effectiveness for other adjuvant therapies.
Interferon
IFNs are signaling proteins released by leucocytes in response to several pathogens, including viruses. Since the 1980s, intramuscular IFN has been used as the most common adjuvant therapy for RRP. Healy et al [18] evaluated the effectiveness of intramuscular IFN to patients with RRP less than 21 years old in a multicenter controlled trial. Their results showed that the growth rate of papillomas in the IFN group was significantly lower than that in the control group during the first 6 months. However, they concluded that IFN was not curative as an adjuvant therapy for long-term management. Gerein et al [19] reported decreased responsiveness to IFN therapy in patients with HPV type 11 in comparison to those with HPV type 6. Systemic toxicity, such as leukopenia, thrombocytopenia, and hepatic and renal dysfunction, is also an important limitation to IFN therapy. As a result, although IFN has historically been the most popular form of adjuvant therapy (used in 9% of patients with JoRRP in 1994), its use had declined to less than 4% in 2004 [15] .
Cidofovir
Cidofovir is an analog of cytosine that has antiviral activity against DNA viruses such as herpes viruses, adenovirus, and HPV in vitro. The US Food and Drug Administration approved cidofovir for the treatment of cytomegalovirus retinitis in patients with human immunodeficiency virus. In 1998, Snoeck et al [20] reported that intralesional cidofovir was administered to 17 patients with RRP aged 11 to 77 years and resulted in complete initial clinical response in 14 of them. Several additional studies subsequently showed the effectiveness of cidofovir [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] , and it had been one of the most widely used alternative adjuvant therapies until HPV4 was introduced in 2006 [15, 33] . However, the majority of these studies included a small sample size and lacked a control group. Only 1 prospective double-blind placebo-controlled longitudinal adjuvant therapy trial has determined the efficacy of cidofovir [34] . Nineteen patients with RRP (including 5 with JoRRP) were assigned randomly to a cidofovir (n = 10) or placebo (n = 9) group. Significant improvement in clinical scores was found in both the cidofovir and control groups; however, the difference between the groups was not significant. For safety considerations, serious adverse effects, including nephrotoxicity, neutropenia, and oncogenicity, were reported after off-label cidofovir use in 2011 [30] . Subsequently, Tjon Pian Gi et al [35] reported no clinical evidence of significant adverse effects after the use of intralesional cidofovir in patients with RRP.
Acyclovir
The effectiveness of oral or intravenous acyclovir for RRP has been reported in some case series [36] [37] [38] [39] . However, the activity of acyclovir depends on the virally encoded thymidine kinase, and HPV has no acyclovir-sensitive thymidine kinase [40] . Therefore, the effectiveness of acyclovir in patients with RRP is assumed to depend on effectiveness for coinfecters such as herpes simplex virus, cytomegalovirus, and Epstein-Barr virus.
Because coinfection in patients with JoRRP is rare [41] , the mechanism of acyclovir in patients with JoRRP remains obscure.
Ribavirin
Ribavirin is a guanosine nucleotide analog that has a wide spectrum of antiviral activity against both RNA and DNA viruses. It has a defined role in the treatment of hepatitis C and respiratory syncytial virus. Although some case reports have described the effectiveness of oral or inhaled ribavirin in patients with RRP [42] [43] [44] , the amount of evidence is inadequate because of the lack of controlled studies.
Indole-3-carbinol
I3C is a nutritional supplement found in high concentrations in cruciferous vegetables such as sprouts, cabbage, broccoli, and cauliflower, and it has been shown to decrease papillomatous growth in vitro by altering estrogen metabolism. Rosen and Bryson [45] reported the results of a prospective open-label study in which orally administered I3C was evaluated as a treatment for RRP. A total of 33 patients with RRP, including 9 with JoRRP, were treated by I3C, and 67% (22 of 33) of the patients had either a complete or partial response to the intervention. However, the complete and partial response rates were lower among the patients with JoRRP (44%) than among those with AoRRP. I3C has an advantage for pediatric patients, because it is noninvasive and administered orally. However, no other studies of this agent for the treatment of RRP have been planned [14] .
HspE7
HspE7 is a recombinant fusion protein of Mycobacterium bovis bacille Calmette-Guerin (BCG) heat-shock protein 65 (Hsp65) and E7 protein from HPV type 16 [14] . Derkay et al [46] reported a case series of 27 patients with JoRRP who received HspE7 subcutaneously and seemed to improve significantly (reduction in the number of required surgeries). However, that study lacked a control group. A prospective controlled study is necessary to establish the validity of these preliminary findings to determine the clinical efficacy of HspE7.
Mumps Vaccine
Pashley [47] treated 18 patients with JoRRP and 20 patients with AoRRP with intralesional mumps vaccine and achieved remission rates of 78% and 75%, respectively. However, that study also lacked a control group, and the mechanism of activity for the mumps vaccine also has not been elucidated completely. Lei et al [48] conducted a pilot randomized controlled trial to measure the efficacy of topical measles-mumps-rubella (MMR) vaccine in 15 patients with JoRRP. According to their report, patients in the MMR group experienced a period of recurrence-free remission that was longer than that in the control group; however, the difference was not statistically significant.
Photodynamic Therapy
PDT was developed originally for the treatment of cancer. It requires an injectable photosensitizer and promotes apoptosis by laser excitation of the agent. Shikowitz et al [49] evaluated the efficacy of PDT in 23 patients with RRP aged 4 to 60 years in a parallel-arm controlled trial and concluded that PDT reduced the severity of RRP. However, the quality of the evidence is still inadequate to establish clinical efficacy [50] .
Propranolol
Propranolol is a nonselective β blocker that has been used for the treatment of hypertension and migraine. Maturo et al [51] introduced oral propranolol to 3 severely affected patients with JoRRP as an adjuvant therapy, and 2 of them experienced some efficacy as measured by delayed surgical intervention and improved clinical symptoms. However, propranolol has not been evaluated further in a controlled study, and the quality of the evidence remains inadequate to establish clinical efficacy.
Cimetidine
Cimetidine is an H 2 -receptor antagonist (H2RA) that is used for the treatment of gastric ulcers. Under the hypothesis that complicated laryngopharyngeal reflex disease is a risk factor for more severe or progressive RRP [14] , Harcourt et al [52] introduced high-dose cimetidine to a 10-year-old girl with severe JoRRP. She had remarkable improvement in her clinical condition after treatment. However, this was a single case report; further evaluation with controlled studies is needed.
Bevacizumab
Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and blocks interaction with the VEGF receptor. Some case reports have described the effectiveness of bevacizumab in patients with RRP [53] [54] [55] [56] [57] [58] . Rogers et al [55] administered intralesional bevacizumab therapy to 10 patients with JoRRP. According to their results, after introducing bevacizumab, the median duration of time between surgical procedures increased by 5.9 weeks, and the median number of procedures per year decreased by 4. In recent years, the safety of intralesional highdose therapy [54, 57] or intravenous systemic therapy [56, 58] in patients with AoRRP and in patients with JoRRP also was reported.
VGX-3100
Therapeutic HPV vaccines are in development. Trimble et al [59] reported the safety and efficacy of therapeutic synthetic DNA vaccine targeting HPV types 16 and 18 E6 and E7 proteins. Interactions of the E6 and E7 proteins with apoptotic p53 and Rb protein lead to the disruption of normal growth regulatory mechanisms that cause cervical cancer. At the present time, it is not clear whether a therapeutic vaccine would have any effect on JoRRP. Because E6 and E7 proteins from HPV types 6 and 11, which are main causes of JoRRP, do not readily bind to or degrade the p53 or Rb protein [60] , which indicates that the mechanisms of JoRRP are different from those of cervical cancer.
To identify effective adjuvant treatment options for JoRRP, it is necessary to carry out multicenter prospective randomized controlled studies. In addition, an evaluation of the effectiveness of combination adjuvant therapies is needed also. However, because JoRRP is a rare disease and clinical courses vary individually, we assume it to be extremely difficult to carry out such studies with sufficient power to yield reliable results.
Once JoRRP develops, the clinical course is extremely complicated. Therefore, a more effective strategy for preventing JoRRP might be to prevent maternal HPV infection. Although no clear evidence is available to indicate whether HPV4 used for adolescents and young adults will prevent JoRRP in their children directly, it is well established that HPV4 is highly efficacious in the prevention of genital warts, which is a risk factor for JoRRP. [61] . In addition, the number of reported cases of JoRRP declined from 7 cases in 2012 to 3 cases in 2013 and 2 cases in 2014 [62] .
In the United States, HPV vaccines were first approved in 2006, and a 9-valent HPV vaccine was introduced in December 2014. Despite an excellent safety and efficacy profile, immunization rates are inadequate; only approximately 40% of adolescent girls have completed the HPV vaccine series in the United States [63] . In Japan, the Ministry of Health, Labour and Welfare suspended its active recommendation of HPV vaccination after alleged adverse events in 2013. As a result, HPV vaccination coverage among adolescents in Japan is less than 1% [64] . If such low HPV vaccination coverage persists, more cases of anogenital cancers that could have been prevented and more cases of genital warts that can lead to JoRRP will occur.
There are some limitations in this case report. First, we could not evaluate immune response to HPV4 to determine whether immunogenicity in this young patient affected our results. Second, using HPV4 for a 2-year-old boy is an off-label indication, and few data on vaccine efficacy and safety in this age group are available. Last, this case report does not allow for a definitive evaluation of HPV4 effectiveness as an adjuvant therapy for patients with JoRRP.
CONCLUSION
The efficacies of adjuvant therapies, including the therapeutic use of HPV4, for children with JoRRP are uncertain. Therefore, prophylactic use of the currently available HPV vaccine for adolescent boys and girls is the most effective strategy for preventing not only anogenital cancers but also genital warts, which might pose a risk for JoRRP among their children in the future. 
